Pathak emphasized the importance of not only speaking with a health care professional about whether GLP-1s are a good fit, but also implementing healthy lifestyle behavior changes
The perspective that GLP-1s are a quick fix to obesity is in sharp contrast to the medical communitys recognition of obesity as a chronic disease, designated as such by the American Medical Association in 2013
Contemporary Pediatrics, 40(5), 36-38
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial
Significant weight loss has traditionally been quantified as total body weight loss of 5 percent or more orforglipron exceeded that in this trial, says Dr